Indian vaccine maker working on a range of low-priced products
Serum's offerings threaten to undercut brands from the world's biggest pharma firms
Mumbai
ASIA'S biggest vaccine maker is working on a string of new low-priced offerings that threaten to undercut brands from the world's biggest pharmaceutical companies.
Serum Institute of India Ltd, which makes vaccines injected in 65 per cent of the world's children, is targeting newer vaccines, including one for the human papillomavirus (HPV) that could be available in late 2018 and sell at a third of the price of Merck & Co's blockbuster Gardasil. Also in development are vaccines for types of severe diarrhoea and pneumonia.
The version of the HPV vaccine will initially be launched in developing countries and Serum aims…
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Japan’s 7-Eleven convenience chain targets aggressive global growth
Bubble tea maker Chabaidao slumps 10% in Hong Kong’s biggest 2024 debut
Parental fury after stem cell bank ruins thousands of samples in Singapore
China’s bubble tea boom creates a half-dozen billionaires
US sues to block Coach owner’s US$8.5 billion buyout of Versace parent
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO